STOCK TITAN

American Oncology Network Welcomes Robert J. McDonald, MD, FACNM, as Radiology Medical Director and In-House Reading Radiologist

(Moderate)
(Very Positive)
Tags

American Oncology Network (NASDAQ:AONC) announced the appointment of Robert J. McDonald, MD, FACNM, as Radiology Medical Director and in-house reading radiologist, effective Dec. 10, 2025. Dr. McDonald will serve as primary reading radiologist for Florida Oncology & Hematology in Naples and Fort Myers and Central Georgia Cancer Care in Macon, provide PET/CT interpretations, perform advanced radiotheranostic therapies at Naples and Fort Myers, and oversee radiology services at supported practices.

He will lead NRC-required clinical preceptorships, refine RLT protocols, and support rollout of newly FDA-approved radiotheranostic therapies as AONC expands RLT capabilities into 2026. Dr. McDonald brings >30 years of diagnostic imaging and radioligand therapy experience.

Loading...
Loading translation...

Positive

  • Designated Radiology Medical Director across multiple AONC partner sites
  • Primary reading radiologist for FOH Naples, FOH Fort Myers, and CGCC Macon
  • Will perform advanced radiotheranostic therapies at Naples and Fort Myers
  • Will conduct NRC-required clinical preceptorships onsite to expand RLT expertise
  • Over 30 years of diagnostic imaging and radioligand therapy experience

Negative

  • None.

News Market Reaction – AONC

-45.59%
-45.59% Session move

In the trading session that priced this news, AONC declined 45.59%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -45.6% in the session following this news. A negative reaction despite strategic h...
Analysis

The stock dropped -45.6% in the session following this news. A negative reaction despite strategic hiring would fit past instances where academically focused news did not support the share price, such as the ASCO Quality 2025 abstracts release, which saw a -1.47% move. In such scenarios, concerns might center on execution risk around network expansion and radiotheranostic rollout, as well as broader sector sentiment, rather than the immediate fundamentals outlined in the announcement.

Key Figures

Experience: more than 30 years Program expansion year: 2026 Annual revenue: $2 billion +5 more
8 metrics
Experience more than 30 years Diagnostic imaging and radioligand therapies experience for Dr. McDonald
Program expansion year 2026 Target year to bring advanced RLT treatments to more sites
Annual revenue $2 billion 12 months ended June 30, 2025
Revenue growth 40% Year-over-year revenue growth to June 30, 2025
Provider count more than 300 Oncology and hematology providers across 20 states
States covered 20 states Geographic footprint of AON network
CMS cost savings $6 million Value-based care performance
Commercial savings $2.7 million Value-based care performance

Historical Context

5 past events · Latest: Oct 10 (Positive)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Oct 10 Research presentations Positive -1.5% ASCO Quality 2025 acceptance of 15 research abstracts highlighting value-based care.
Oct 07 Physician addition Positive +0.3% Addition of Dr. Chitra Rajagopal to The Center for Cancer and Blood Disorders.
Sep 02 Physician addition Positive +2.8% Genesis Cancer and Blood Institute welcomed Dr. Beau Hilton to its care team.
Aug 12 Growth update Positive +2.0% Report of >$2B annual revenue, >40% growth, and expanded provider network.
Jul 24 Lab reaccreditation Positive +15.6% Central lab reaccreditation by College of American Pathologists in Fort Myers.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Operational and accreditation milestones have often aligned with positive price reactions, while research-focused updates have shown at least one divergence.

Recent Company History

Over the past six months, American Oncology Network reported strong operational progress and network expansion. In July 2025, central lab reaccreditation coincided with a 15.56% gain. An August 2025 update highlighted revenue above $2 billion and over 40% growth, with shares up 2%. Multiple physician additions in September and October 2025 supported geographic expansion. A research-focused ASCO Quality 2025 abstracts announcement on Oct 10 saw a modest -1.47% move, showing that academic visibility has not always translated into near-term stock strength.

Key Terms

radiotheranostics, radioligand therapies, pet, nuclear medicine, +3 more
7 terms
radiotheranostics medical
"Dr. McDonald’s Role Supports AON’s Growth in Radiotheranostics and network-wide RLT"
Radiotheranostics are medical agents that combine diagnosis and treatment by using the same or closely related radioactive compound to both find disease locations and deliver targeted radiation therapy. Think of it like a GPS-guided delivery that first lights up the exact problem on a scan and then sends a focused dose to that spot. For investors, radiotheranostics matter because they can shorten development time, create integrated imaging-and-therapy product lines, and carry distinct regulatory, manufacturing and reimbursement considerations that affect commercial potential and risk.
radioligand therapies medical
"The Nuclear Regulatory Commission (NRC) requires new Authorized Users of radioligand therapies"
Radioligand therapies are treatments that combine a molecule that seeks out specific disease cells with a small radioactive particle, delivering radiation directly to those cells much like a guided missile delivers a warhead to a target. They matter to investors because successful therapies can create new, high-value products and revenue streams while also carrying clinical, regulatory and manufacturing risks that can dramatically affect a company’s valuation and future prospects.
pet medical
"providing expert interpretations for PET and CT imaging."
Positron emission tomography (PET) is a medical imaging test that creates a live map of how organs and tissues are working by tracking a tiny, safe amount of radioactive tracer inside the body. For investors, PET matters because it’s often used in clinical trials and diagnosis to show whether a drug or treatment is affecting disease — think of it as a performance meter that can speed regulatory decisions, change market forecasts, and affect a product’s commercial value.
nuclear medicine medical
"board-certified nuclear medicine physician – as Radiology Medical Director"
Nuclear medicine uses very small amounts of radioactive substances to create images of the body or deliver targeted treatments; think of it like a tracer dye that lights up organs on a scan or a guided missile that seeks out and treats diseased tissue. It matters to investors because technological advances, regulatory approvals, and clinical adoption directly affect sales of specialized drugs, imaging equipment, and hospital services, influencing revenue, growth prospects, and regulatory risk for healthcare companies.
nuclear regulatory commission regulatory
"The Nuclear Regulatory Commission (NRC) requires new Authorized Users"
The Nuclear Regulatory Commission is a government agency responsible for overseeing the safety and security of nuclear power plants and radioactive materials. It sets rules and monitors practices to prevent accidents and protect public health. For investors, its regulations can influence the stability and operation costs of nuclear energy companies, affecting their long-term viability.
radioligand medical
"expansion of radioligand expertise across the network."
A radioligand is a small molecule or protein tagged with a tiny amount of radioactivity that seeks out and binds to a specific target in the body, like a GPS-enabled probe that lights up a particular protein or tissue. Investors care because radioligands are used for diagnostic imaging and targeted treatments, so successful development, regulatory approval, or adoption can create clear revenue pathways and affect valuation for companies in diagnostics and therapeutics.
fda-approved regulatory
"rollout of newly FDA-approved radiotheranostic therapies"
FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Dr. McDonald’s Role Supports AON’s Growth in Radiotheranostics and Network-Wide RLT Capabilities

FORT MYERS, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- American Oncology Network (AON), one of the nation’s fastest-growing community oncology networks, is pleased to announce the addition of Robert J. McDonald, MD, FACNM – a nationally recognized, board-certified nuclear medicine physician – as Radiology Medical Director and in-house reading radiologist. In this role, Dr. McDonald will support AON’s strategic expansion of radiotheranostic services throughout the network and strengthen AON’s commitment to delivering cutting-edge cancer care close to where patients live and work.

13719_AON_Robert-McDonald_Press-Release_Headshot_251204_V1 (3)Dr. McDonald will serve as the primary reading radiologist for AON partner practices Florida Oncology & Hematology (FOH) in Naples and Fort Myers, and Central Georgia Cancer Care (CGCC) in Macon, providing expert interpretations for PET and CT imaging. He will also perform advanced radiotheranostic therapies at the Naples and Fort Myers location, while overseeing radiology services as Medical Director at each practice he supports.

As AON continues to expand its radiotheranostic footprint, Dr. McDonald will play an integral role in developing physicians, supporting future program growth, and bringing advanced RLT treatment options to more AON practice sites in 2026. The Nuclear Regulatory Commission (NRC) requires new Authorized Users of radioligand therapies to complete clinical preceptorships, and part of Dr. McDonald’s position includes conducting these preceptorships on-site when needed, helping ensure safe, timely expansion of radioligand expertise across the network.

In addition, Dr. McDonald will lead clinical refinement of AON’s RLT protocols and assist in the adoption and rollout of newly FDA-approved radiotheranostic therapies – further positioning AON at the forefront of innovation in community oncology.

“AON is at the leading edge of radiotheranostics in community oncology, and Dr. McDonald’s expertise will accelerate our ability to bring groundbreaking radioligand treatments to more patients across the country,” said Todd Schonherz, AON chief executive officer. “His leadership in clinical training, protocol development, and program expansion will be essential as we scale radiotheranostic services to additional AON practice sites in 2026 and beyond. We are proud to welcome him and look forward to what his presence will make possible for our physicians, our practices, and the patients we serve.”

“Bringing Dr. McDonald into these roles allows us to enhance the quality, continuity, and cost-effectiveness of radiological services across our practices,” said Guy Messer, AON vice president of radiation and radiology services. “His expertise strengthens our ability to deliver timely imaging and treatment while also advancing the expansion of radiotheranostics within AON – a core element of our commitment to improving access to next-generation cancer care in community settings.”

Dr. McDonald joins AON with more than 30 years of experience in diagnostic imaging and radioligand therapies. He previously served as the Medical Director of Imaging Services for Florida Cancer Specialists & Research Institute, specializing in PET/CT interpretation and therapeutic nuclear medicine.

His career includes leadership appointments at MD Anderson Cancer Center Orlando, extensive work with Radiology Regional Center in Southwest Florida, and leadership positions in major medical centers in Oregon and California. He has also held multiple leadership roles within the Society of Nuclear Medicine & Molecular Imaging and is a Fellow of the American College of Nuclear Medicine.

Dr. McDonald is a respected researcher, educator, and speaker who has contributed to numerous clinical studies and national presentations advancing nuclear medicine. He earned his medical degree from the Medical College of Virginia and completed his nuclear medicine residency at the University of California Irvine Medical Center.

About American Oncology Network
American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 300 providers practicing across 20 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com or follow us on LinkedInFacebookX (formerly Twitter) and YouTube.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f6a63acb-8ae5-4362-ac2b-f9af8d46ae1d



Contact:
Karen Riley Sawyer
American Oncology Network
Karen.Sawyer@AONcology.com

FAQ

Who is Robert J. McDonald and what role did AONC announce on Dec. 10, 2025?

AONC named Robert J. McDonald, MD, FACNM, as Radiology Medical Director and in-house reading radiologist supporting network radiotheranostic expansion.

Which AONC partner practices will Dr. McDonald support as primary reading radiologist (AONC/AONC ticker AONC)?

He will serve as primary reading radiologist for Florida Oncology & Hematology in Naples and Fort Myers, and Central Georgia Cancer Care in Macon.

What clinical responsibilities will Dr. McDonald have at AONC starting Dec. 2025?

He will interpret PET/CT, perform advanced radiotheranostic therapies at Naples and Fort Myers, oversee radiology services, and run NRC-required preceptorships.

How will Dr. McDonald affect AONC’s radiotheranostic rollout in 2026?

He will support protocol refinement, clinician training, and adoption of newly FDA-approved radiotheranostic therapies to expand RLT to more AONC sites in 2026.

Does the announcement specify financial or patient-volume impacts for AONC (AONC)?

No; the announcement describes clinical and operational roles but does not provide financial figures or patient-volume projections.

What qualifications does Dr. McDonald bring to AONC’s radiology and RLT programs?

He holds >30 years of experience in diagnostic imaging and radioligand therapies, prior imaging medical director roles, and fellowship and leadership positions in professional societies.